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Abstract
CCL2 is a cytokine prevalent in the prostate cancer tumor microenvironment. Recently, we reported that CCL2 in-
duces the mammalian target of rapamycin (mTOR) pathway to promote prostate cancer PC3 cell survival; however,
themechanism used by CCL2 tomaintainmTOR complex-1 (mTORC1) activation requires clarification. This study dem-
onstrates that upon serum starvation, CCL2 functions as a negative regulator of AMP-activated protein kinase (AMPK)
by decreasing phosphorylation at its major regulatory site (Thr172) in PC3, DU145, and C4-2B prostate cancer cells. The
CCL2-mediated AMPK regulation decreased raptor phosphorylation (Ser792) resulting in hyperactivation of mTORC1.
D942, a pharmacological activator of AMPK, stunted CCL2-induced mTORC1 activity, survivin expression, and cell
survival without significantly affecting Akt activity. CCL2, however, conferred some resistance to the lethal effect of
D942 compared with untreated cells. By using Akt-specific inhibitor X, it was shown that Akt inactivation did not cause
an increase in AMPK phosphorylation in CCL2-stimulated cells, suggesting that CCL2-mediated negative regulation of
AMPK is independent of Akt. Furthermore, bisindolylmaleimide-V, a specific inhibitor of p70S6K, stunted survivin ex-
pression and induced cell death in CCL2-treated PC3. Altogether, these findings suggest that CCL2 hyperactivates
mTORC1 through simultaneous regulation of both AMPK and Akt pathways and reveals a new network that promotes
prostate cancer: CCL2-AMPK-mTORC1-survivin.
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Introduction
AMP-activated protein kinase (AMPK) operates as a cellular energy
sensor that is highly specific for AMP and is acutely sensitive to changes
in the AMP/ATP ratio. Excessive nutrient depletion or exposure to
metabolic stressors rapidly decreases intracellular ATP; the commen-
surate accumulation of AMP thereby switches on AMPK-mediated
energy-generating catabolic processes and turns off energy-consuming
processes such as protein synthesis [1–7]. Binding of AMP is thought to
enhance AMPK activity both by inducing conformational changes,
making AMPK a better substrate for phosphorylation by upstream
kinases, including LKB1 (AMPK kinase [AMPKK]), and by prevent-
ing subsequent dephosphorylation [1,8]. Conversely, binding of ATP
to either the catalytic or the allosteric site antagonizes activation by
AMP [8].
Activated AMPK responds by negatively regulating mammalian tar-
get of rapamycin (mTOR)–dependent signaling [9]. mTOR operates
as a nutrient-sensitive modulator of biogenic and metabolic functions
through regulation of key processes, including induction of protein
synthesis and inhibition of autophagy [10,11]. mTOR, however, is
strictly controlled by interactions with critical binding partners; indeed,
mTOR has been confirmed to function as a larger signaling complex
(mTORC1), comprising itself and three other subunits: mLST8/GβL,
proline-rich Akt substrate 40 (PRAS40), and the regulatory-associated
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protein of mTOR, raptor [6,11,12]. Raptor interacts directly with
mTOR through multiple binding domains and functions as a critical
scaffold protein to present regulatory and target substrates (PRAS40,
S6K, and eIF4E-binding proteins) to mTORC1 [12,13]. Binding of
PRAS40 to the mTORC1 signaling complex attenuates mTOR ac-
tivity, presumably by inhibition of downstream substrate binding;
however, phosphorylation of the Thr246 residue by Akt/PKB relieves
PRAS40-mediated mTOR inhibition [13].
It has recently been reported that mTORC1 inhibition, in response
to metabolic stress, requires the direct phosphorylation of raptor
(Ser792) by AMPK [10]. This inhibition of mTORC1 by AMPK is ab-
solutely essential for activation of the catalytic, ATP-generating pro-
cess, macroautophagy (herein called autophagy). Importantly, it has
been revealed that even basal AMPK activity is sufficient to induce
autophagy [5]. In extreme intracellular milieus, cancer cell survival is
contingent on acute regulation of energy-consuming processes. Auto-
phagic catabolism of intracellular materials provides the necessary con-
stituents tomaintain cellularmetabolism. Upon induction of autophagy,
unnecessarymacromolecules, protein aggregates, and entire organelles are
sequestered within double-membrane–bound vesicles (autophagosomes)
and delivered to endocytic lysosomes to be degraded, thereby generating
these requisite elements. However, autophagy itself is an ATP-consuming
process, and consequently, strict regulation is crucial [14–17].
Microtubule-associated protein LC3 is widely used in monitoring
autophagy [18]. Upon induction of autophagy, LC3-I is cleaved and
conjugated to phosphatidylethanolamine to form LC3-II, a process that
is essential for the formation of the autophagosome [19]. Changes in
LC3 localization occur as a result of its recruitment to autophagic mem-
branes, and a remarkable increase in punctate LC3 is observable owing
to LC3-II colocalization with the autophagosome membranes. There-
fore, the amount of LC3-II serves as a good indicator of the number of
autophagosomes and of autophagy.
The connection between chemoattractants and inflammation has
important implications in tumor progression. It is widely accepted
that cytokines elicit a host of responses in the tumor microenviron-
ment, resulting in cell proliferation, differentiation, tumorigenesis,
and, recently, in survival [20–23]. CCL2 (monocyte chemoattractant
protein-1) is commonly recognized to play a significant role in prostate
cancer neoplasia and invasion and is highly expressed in the tumor
microenvironment by human bone marrow endothelial cells [24].
We recently reported that treatment of prostate cancer PC3 cells with
CCL2 elicits a strong survival advantage by phosphoinositide 3-kinase
(PI3K)/Akt–dependent regulation of autophagy through the mTOR
pathway while simultaneously upregulating survivin [25,26]. However,
the mechanisms through which CCL2 upregulates mTORC1 kinase ac-
tivity are still poorly understood. Here, we show that CCL2 activates a
mechanism that acts in parallel to Akt signaling by inhibiting AMPK/
raptor phosphorylation in human prostate cancer PC3 cells. This regu-
lation promotes hyperactivation of mTORC1, sustained survivin expres-
sion, and cancer cell survival.
Materials and Methods
Cell Lines
Human prostate cancer cell lines, PC3 and DU145 were obtained
from ATCC (Manassas, VA). Cells were maintained in RPMI 1640
(Invitrogen, Carlsbad, CA), supplemented with 10% fetal bovine serum
(Invitrogen) and 1% Antibiotic-Antimycotic (Invitrogen). The human
prostate C4-2B cells (UroCor, Inc, Oklahoma City, OK) were derived
from LNCaP cells through several passages through castrated nude mice
and isolated from the tumor that metastasize to bone. C4-2B cells were
maintained in T-medium supplemented with 10% fetal bovine serum
and 1% Antibiotic-Antimycotic.
WST-1 Cell Viability Assay
Dye conversion of 4-[3-(4-idophenyl)-2-(4-nitrophenyl)-2H -5-
tetrazolio]-1,3-benzene disulfonate to formazan (Cell Proliferation
Reagent WST-1; Roche, Nutley, NJ) was used to assess cell viability
and chemosensitivity of PC3 cells. PC3 cells were grown to 80% con-
fluence then serum-starved for 16 hours in RPMI plus 1% Antibiotic-
Antimycotic. Synchronized cells were plated at 104 cells per well into
96-well tissue culture plates (no. 3596; Costar/Corning, Lowell, MA)
and allowed to attach for 6 hours. Cells were then treated with in-
creasing concentrations of pharmacological protein kinase inhibitors
or activators, in the presence and absence of CCL2 chemokine (Apollo
Cytokine Research, Australia), then incubated for 24 to 96 hours. Phar-
macological agents used include Akt specific inhibitor X (10-(4′-(N -
diethylamino)butyl)-2-chlorophenoxazine, HCl; catalog no. 124020;
Calbiochem/EMD Biosciences, San Diego, CA), AMPK inhibitor
compound C ((6-[4-(2-piperidin-1-yl-ethoxy)-phenyl)]-3-pyridin-4-
yl-pyrrazolo[1,5-a]-pyrimidine; catalog no. 171260; Calbiochem),
p70S6K-specific inhibitor bisindolylmaleimide-V (2,3-bis(1H -indol-3-
yl)-N -methylmaleimide; catalog no. 203303; Calbiochem), and AMPK
activator D942 (5-(3-(4-(2-(4-fluorophenyl)ethoxy)phenyl)propyl)
furan-2-carboxylic acid; catalog no. 171256; Calbiochem). WST-1 re-
agent was added following the manufacturer’s instructions, and plates
were returned to 37°C for 105minutes. Dye conversion was ascertained
at 440 nm by a VersaMax Microplate Reader and was analyzed using
Softmax Pro 3.12 software (Molecular Devices, Sunnyvale, CA). Sur-
vival curves were generated using n = 5 sample replicates for each con-
dition ± CCL2 (100 ng/ml). Data for survival curves were normalized
to cells untreated with protein kinase activators or inhibitors for both
CCL2-stimulated and unstimulated cells. SDs were determined for each
set of data points and represented by ±Y error bars.
Western Blot Analysis
Prostate cancer cells (PC3, DU145, C4-2B) were grown to 80%
confluence in the appropriate medium. PC3 and DU145 cells were
synchronized by starvation in serum-free RPMI 1640 for 16 hours at
37°C. Cells were detached using 0.25 mMEDTA pH 8.0 (Invitrogen),
then plated in six-well culture plates at a density of 1.75 × 105 cells/ml.
Cells were allowed to attach for 6 hours before treatment with inhibi-
tors (as specified above) and/or CCL2 (100 ng/ml). C4-2B cells were
plated in complete medium; 16 hours later, the medium was replaced
by serum-free T-medium containing CCL2 (100 ng/ml). After treat-
ment, cells were harvested at increasing time points in cell lysis buffer
(no. 9803; Cell Signaling Technology, Danvers, MA). Protein samples
were sonicated, followed by centrifugation at 13,000 rpm for 10 min-
utes. Supernatants were collected, and protein concentrations were
determined using the Bradford Assay (Bio-Rad, Hercules, CA). Pro-
tein lysates were electrophoresed on 4% to 20% Tris-glycine SDS poly-
acrylamide gels and transferred onto polyvinylidene fluoride according
to Invitrogen instructions. Incubation with antibodies was performed
according to Cell Signaling Technology–recommended procedures.
Primary Antibodies
All antibodies against phospho and respective total protein kinases
evaluated in these experiments were obtained from Cell Signaling
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Technology: phospho-p70S6 kinase-Thr389 (catalog no. 9205), p70S6
kinase (catalog no. 9202), phospho-AMPKα-Thr172 monoclonal
antibody (mAb; catalog no. 2535), AMPKα (catalog no. 2532),
phospho-raptor-Ser792 (catalog no. 2083), raptor mAb (catalog
no. 2280), survivin mAb (catalog no. 2808), phospho-Akt-Ser473
mAb (catalog no. 4060), phospho-Akt-Thr308 mAb (catalog no. 4056),
Akt (catalog no. 9272), phospho-PRAS40-Thr246 (catalog no. 2640),
PRAS40 mAb (catalog no. 2691), LC3B (catalog no. 2775), and β-actin
mAb (catalog no. 4967L).
ATP Determination Assay
PC3 cells were synchronized by serum-starvation for 16 hours at
37°C. After synchronization, cells were plated in duplicate at a density
of 1.75 × 105 cells per milliliter and allowed to attach to plate surfaces
for 6 hours, before treatment, or not, with CCL2 (100 ng/ml). At 48
and 72 hours after treatment, cells were lysed as described above and
then sonicated, and cell debris was removed by centrifugation. ATP
assay was performed using the Invitrogen ATP determination kit
(catalog no. A22066) according to the manufacturer’s recommended
instructions. Briefly, sample lysates were diluted appropriately in cell
lysis buffer, and assay was performed at 28°C in triplicate. Luminescent
readings were acquired using a SpectraMax M5 microplate reader in
combination with SoftMax Pro v5 software (Molecular Devices). Sam-
ple concentrations were calculated based on a standard curve of known
ATP concentrations (included in assay kit), and background levels were
subtracted before final analyses. Cells from duplicate plates were tryp-
sinized and counted using the Invitrogen Countess automated cell
counter to normalize ATP concentrations to cell number. ATP concen-
trations were then expressed as micromolars of ATP per 105 cells.
Statistical Analysis
All average values are presented a means ± SD (SDs). Data were
analyzed using GraphPad Prism software (GraphPad Software, Inc,
La Jolla, CA) and one-way ANOVA combined with Kruskal-Wallis
test or 2-tailed unpaired t-test. P < .05 was considered significant.
Results
CCL2 Signaling Regulates AMPK/Raptor Phosphorylation
in PC3 Cells under Serum Deprivation
Several reports have identified CCL2 as a chemokine that impacts
cancer progression and metastasis. Recently, we reported that CCL2
induces the mTOR pathway in human prostate cancer PC3 cells, and
this activation requires the induction of the PI3K/Akt signaling [25].
Here, we reveal a parallel pathway that leads to mTORC1 activation by
CCL2 in PC3 cells. mTORC1 activation was evaluated by the phos-
phorylation of its target kinase, p70S6K on the Thr389 residue, which is
directly phosphorylated by mTORC1, is sensitive to rapamycin in vivo,
and is required for the p70S6K kinase activity [27]. CCL2 induced and
sustained a higher phosphorylation of p70S6K kinase (Thr389) compared
with serum-starved untreated cells (Figure 1A). Although the Akt
pathway is hyperactivated in PC3 cells, it was reasoned that to maintain
the steady activation of mTOR, another pathway must coexist. This
hypothesis was suggested by the observation that insulin-like growth
factor 1, a factor known to activate Akt, was able to induce early phos-
phorylation of p70S6K, but the stimulation disappeared by 24 hours
[25]. Other reports have emphasized the role of AMPK as a master
sensor of cellular energy status. AMPK, which is activated under con-
ditions of low intracellular ATP resulting from nutrient and serum
deficit, acutely inhibits mTORC1 signaling and induces the autophagy
machinery [5,28]. Accordingly, we investigated the possible regulation
of AMPK by CCL2. When compared with control cells, CCL2 treat-
ment markedly downregulated AMPK phosphorylation on Thr172, an
essential phosphorylation site for the activation of AMPK [29,30] (Fig-
ure 1B). A densitometric analysis of (phospho-AMPK)/(total AMPK)
is shown in the bar graph (Figure 1B) and corroborates the down-
regulation of AMPK phosphorylation by CCL2. Furthermore, it was
recently demonstrated that AMPK directly phosphorylates raptor on
Ser792 to inhibit mTORC1 [10]. Consistent with the negative regula-
tion of AMPK, CCL2-treated cells also showed a significantly lower
raptor phosphorylation on Ser792 (Figure 1B, bar graph). In contrast,
control cells exhibited a sustained up-regulation of phospho-AMPK
in time, which also correlated with the increase in phospho-raptor
(Ser792) and the inhibition of mTOR activity (lower phospho-p70S6;
Figure 1, A and B).
Figure 1. CCL2 induces mTORC1 activation and downregulates
AMPK/raptor phosphorylation in serum-starved PC3 cells. (A and B)
Immunoblot analysis depicting the time-dependent effect of CCL2
(100 ng/ml) on (A) phosphorylation of the p70S6 kinase (Thr389 resi-
due), a direct target of mTORC1, and (B) AMPK/raptor phosphory-
lation and its correlation with survivin up-regulation. Reduction of
AMPK and raptor phosphorylation, in response to CCL2 treatment,
was quantified by densitometric analysis; the relative change in
spot density was compared with total respective proteins and was
normalized to actin (shown in respective bar graphs to the right). (C)
Quantification of PC3 cellular ATP 48 and 72 hours for control and
CCL2-treated cells. Bar graph depicts ATP concentration (μM per
1 × 105 cells), and is representative of n = 3 bioluminescent ATP
determination assays.
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Because AMPK is acutely sensitive to changes in the AMP/ATP
ratio, the effect of CCL2 on intracellular ATP was further investigated.
Thus, a quantitative determination of ATP in cell lysates at 48 and
72 hours, for control and CCL2-treated cells, was performed by using
an ATP bioluminescence assay. The results shown in Figure 1C demon-
strate a decrease in the ATP levels in time, but no significant differences
were observed between untreated and CCL2-stimulated cells. There-
fore, the down-regulation of AMPK phosphorylation could not be
explained by the CCL2-induced metabolic changes that affect the
ATP concentration in the cell.
CCL2-Dependent Regulation of AMPK Signaling Induces
mTORC1 Activation and PC3 Cell Survival
Subsequently, the relevance of AMPK regulation in the mechanism
of CCL2-dependent mTORC1 activation and PC3 cell survival was
addressed. D942 (Calbiochem [31]), an AMPK activator, was used at
concentrations of 10 and 20 μM, and the cell viability was measured at
24-hour increments up to 96 hours in control and CCL2-stimulated
cells. CCL2-treated cells showed a higher cell survival compared with
control cells. D942 generated a minor effect on cell viability at 10 μM
(Figure 2Aa); however, when D942 concentration was increased to
Figure 2. AMPK activator D942 induces raptor phosphorylation and downregulates mTORC1 signaling promoting cell death in PC3, but
CCL2 opposes the lethal effect of D942. Cell viability was evaluated byWST-1 dye conversion at 24-hour increments up to 96 hours. (A) a and
b: Time course for PC3 cell survival in response to D942: 10 μM (a) or 20 μM (b), ±CCL2. Bar graphs corresponding to control and CCL2-
treated cells, without D942, are also included. Improved PC3 survival in response to CCL2 treatment was determined to be significant com-
pared to control at 72 and 96 hours after stimulation, as evaluated by the Student’s t-test; P < .0001 were observed. c: Relative effect of
increasing D942 from 10 to 20 μM for control and CCL2-stimulated cells. Data for all graphs are representative of n= 5 assays, and SDs are
depicted by ±Y error bars for each data point. (B) Western blot analysis using anti–P-Thr172 AMPK and anti–P-Ser792 raptor phospho-specific
antibodies depicts increased AMPK/raptor signaling, in response to D942 treatment (20 μM), 48 hours after treatment. Reduction in raptor
phosphorylation compared with total protein was verified by densitometric analysis (shown in respective bar graph). Akt activation was also
evaluated in response to D942, and the relative change in phospho and total Akt was quantified and analyzed by densitometric analysis with
n = 3 samples (shown in bar graph). Phospho-PRAS40 (Thr246) immunoblots were included as a control for Akt-dependent signaling.
(C) Western blot analysis representing the effect of D942 on: p70S6K phosphorylation (Thr389), survivin expression, and the autophagic
marker LC3-II. Phospho-specific expression was verified by comparison with total respective proteins.
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20 μM, a considerable decrease in cell viability was observed in both
control and CCL2-treated cells (72 and 96 hours after treatment;
Figure 2Ab). Furthermore, CCL2 opposed the effect of D942 in cell
viability. In fact, as shown in Figure 2Ac, the ratio of [10 μM D942]/
[20 μMD942]WST-1 values, corresponding to 72 and 96 hours, dem-
onstrates a greater reduction in cell viability for control cells compared
with CCL2-stimulated cells. Conversely, no significant differences were
observed at earlier time points (24-48 hours), which correlates with
lower levels of AMPK activation (see Figure 1B). These results indicate
that CCL2 promotes cell survival and mitigates the lethal effect of
D942 in PC3 cells, suggesting that the negative regulation of AMPK
is essential in the CCL2-induced cell survival mechanism. To under-
stand the effect of AMPK activation in PC3 cell signaling mecha-
nisms, cell extracts from control and CCL2-stimulated cells, treated
or not with 20 μM D942, were collected 48 hours after treatment
and subjected to immunoblot analysis. The activation of AMPK by
D942 was confirmed by the observed increase in Thr172 phosphoryla-
tion (compare lanes 1 and 2 and lanes 3 and 4, Figure 2B). Furthermore,
the increase in AMPK activation induced phosphorylation of raptor on
Ser792 (Figure 2B, bar graph), corroborating recent findings that raptor
is a direct AMPK substrate [10]. As a result, raptor phosphorylation
inhibited mTORC1 activity as was demonstrated by a striking decrease
in phospho-p70S6K in response to D942 (Figure 2C ). Consequently,
the stunted mTORC1 activity abruptly abrogated survivin expression
in CCL2-treated cells (compare lanes 3 and 4, Figure 2C). These results
were accompanied by an increase in LC3B (compare lanes 1 and 2
and lanes 3 and 4, Figure 2C ) correlating with reduced cell survival as
previously reported [25]. However, it was necessary to determine if
D942 also affected Akt activation. Although the phospho-Akt (Ser473
and Thr308) levels were slightly reduced by the activator, the ratios of
(phospho-Akt)/(total Akt) remained equal, as the total Akt levels were
also reduced (Figure 2B, bar graph). The unaffected Akt activation by
D942 was further corroborated by the analysis of the downstream tar-
get PRAS40, which has previously been identified as a raptor binding
protein and mTORC1 inhibitor [32,33]. Indeed, as PRAS40 is phos-
phorylated by Akt on Thr246 [32], an Akt inhibition would also result
in PRAS40 inhibition. As shown in Figure 2B, no differences were ob-
served in PRAS40 phosphorylation (compare lanes 1 and 2 or lanes 3
and 4 ), indicating similar Akt activation. Altogether, our results suggest
that the inhibition of mTORC1 activity and the increased cell death by
D942 are a consequence of AMPK activation rather than changes in the
Akt activity, and therefore, the down-regulation of AMPK activity by
CCL2 is essential to control mTORC1 activity and cell survival.
Full Activation of mTORC1 and Cell Survival by CCL2
Stimulation Requires Both Positive Regulation of Akt and
Negative Regulation of AMPK
The role of AMPK in CCL2 signaling was further investigated
by using an ATP competitive inhibitor of AMPK, compound C
(dorsomorphin) [34]. PC3 cell survival was analyzed in the presence
of 20 μM of compound C. The inhibitor induced rapid cell death in
both control and CCL2-stimulated cells (Figure 3A). Immunoblot
analysis of cell extracts, treated or not with compound C, evidenced
substantial inhibition of raptor phosphorylation on Ser792 (compare
lanes 1 and 2 with lanes 3 and 4, Figure 3B). Because raptor is a
downstream target of AMPK, this result demonstrated the effective
inhibition of AMPK activity by compound C. However, when Akt
signaling was analyzed, it was obvious that strong inhibition of Akt
phosphorylation was also induced by compound C both in control
and CCL2-treated cells (Figure 3B). This Akt inactivation was also
reflected by the inhibition of phospho-PRAS40 (Thr246). Consequently,
p70S6K phosphorylation was also inhibited (Figure 3C ), correlating
with down-regulation of survivin expression, up-regulation of autophagy
(higher LC3-II levels), and an increase in cell death (Figure 3, A and C).
In summary, although reduced raptor phosphorylation was achieved,
the overall effect of compound C resulted instead in the inhibition of
mTORC1, which could be explained by the inactivation of the Akt
pathway. These results and the above findings with the AMPK activator
D942 strongly suggest that both the positive regulation of Akt and the
negative regulation of AMPK act in parallel and are required for the
full mTORC1 activation. Thus, CCL2 hyperactivates mTORC1 via a
coordinated regulation of two signaling pathways: Akt and AMPK.Here,
induction of PC3 cell death is the consequence of reduced p70S6K acti-
vation by high AMPK phosphorylation or low Akt activation.
By using the Akt-specific inhibitor X (Akti-X [25,35]), it was fur-
ther demonstrated that CCL2-mediated regulation of AMPK is in-
dependent of Akt activation. It was hypothesized that if Akt activation
induced a negative regulation of AMPK, as previously reported in other
cells [36,37], then Akt inhibition would result in the up-regulation
of AMPK phosphorylation. Figure 3D shows that Akti-X effectively
inhibited Akt phosphorylation at Ser473 and Thr308 (both residues are
necessary for full Akt activation). Similarly, phosphorylation of a down-
stream target PRAS40 was inhibited by Akti-X. However, no up-
regulation was observed in phospho-AMPK (Thr172), even in lanes 4
and 5 (Figure 3D), where Akt activation was almost completely stunted
by Akt inhibitor X. Conversely, LC3-II dose-dependently increased in
response to Akti-X, correlating with an increase in both autophagy and
cell death, as previously described [25]. These results strongly suggest
that AMPK signaling is regulated by CCL2 independently of Akt ac-
tivation to induce mTORC1 activity and PC3 cell survival.
p70S6 Kinase Phosphorylation at Thr389 Is Strictly Required
for the CCL2-Mediated Survivin Up-regulation and PC3
Cell Survival
Next, the relevance of p70S6K activation in theCCL2-mediatedmech-
anism of PC3 cell survival was evaluated. The analysis was performed
using a cell-permeable compound: bisindolylmaleimide-V (Bis-V),
which blocks the activation of p70S6K (IC50 ∼ 8 μM) but has been
determined to be inactive for other kinases such as phosphoinositide-
dependent protein kinase 1, Akt, protein kinase A, and protein kinase C
(IC50 > 50 μM) [38,39]. Previous reports showed that Bis-V inhibition
of p70S6K is independent of the upstream activator mTOR and that
the residue Thr389 is the critical site for this inhibition [38]. Cell viabil-
ity assays demonstrated that PC3 both untreated and CCL2-treated
cells were in fact sensitive to Bis-V (8 μM; Figure 4A). However, CCL2-
treated cells mitigated the effect of p70S6K inhibitor and demonstrated
a higher survival at 72 hours after treatment (Figure 4A). Immunoblot
analysis of protein extracts revealed an effective blocking of p70S6K
phosphorylation by Bis-V (Figure 4B). The inhibitor significantly re-
duced survivin expression, and consequently, higher levels of LC3-II
were observed (Figure 4B, lanes 6 and 8), which correlated with an
increase in both autophagy and cell death, as previously reported
[25]. Interestingly, the LC3-II increase was higher in control cells than
in CCL2-treated cells (compare lanes 6 and 8, Figure 4B), confirming
a regulatory role of CCL2 in the control of autophagy. Furthermore,
the inhibition of survivin by Bis-V strongly suggests that p70S6K acti-
vation by phosphorylation at Thr389 is essential in the mechanism of
CCL2-mediated survivin up-regulation and PC3 cell survival. Because
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p70S6K is regulated by AMPK, this result also links the CCL2-induced
cell survival pathway through survivin up-regulation with the control
of AMPK activation.
CCL2 Regulates the AMPK Signaling in C4-2B and DU145
Prostate Cancer Cells
The effect of CCL2 in the regulation of AMPK signaling was
investigated in C4-2B and DU145 prostate cancer cells upon serum
deprivation. Cell lysates from control and CCL2-stimulated cells were
collected at different times for the analysis of AMPK activation by
Western blot. The results revealed that CCL2 negatively regulated
AMPK phosphorylation in both C4-2B and DU145 cells compared
with control cells (Figure 5, A and B, bar graphs). These results also
correlated with higher phosphorylation of the downstream target raptor
(Ser792), suggesting that analogous mechanisms for the negative regu-
lation of AMPK could be activated in other prostate cancer cells to in-
duce mTORC1 signaling and promote survival in cells under nutrient
depletion stress.
Discussion
The cellular response to a shortage of environmental nutrients and
resultant loss in energy is a critical pathologic event. Autophagy is an
Figure 3. AMPK inhibitor, compound C, stunts Akt-dependent signaling, and PC3 cell survival. (A) Cell viability was evaluated by WST-1
dye conversion at 24 and 48 hours. PC3 cell viability graph bars in response to compound C (20 μM) are shown for control and CCL2-
stimulated cells. The data are representative of n = 5 assays for each CCL2-stimulated and control cells. SD bars are depicted for each
data point. (B) Western blot depicting reduced AMPK activity in response to compound C (20 μM) in cells treated or not with CCL2 as
evaluated by raptor phosphorylation (Ser792). The blots also show how compound C hinders Akt activation by inhibiting phosphorylation
of key activation sites (Ser473 and Thr308) and thus preventing phosphorylation of a downstream target PRAS40 (Thr246). (C) Immunoblot
analysis illustrating the effect of compound C at 24 hours on p70S6K phosphorylation (Thr389), survivin expression, and the autophagic
marker LC3-II. (D) CCL2 regulates AMPK signaling through an Akt-independent mechanism. Serum-starved, CCL2-stimulated PC3 cells
were treated with increasing concentrations (1.25, 2.5, and 5 μM) of Akt inhibitor Akti-X (Calbiochem). Western blot analysis reveals how
Akti-X effectively inhibits Akt activation/phosphorylation (Ser473 and Thr308) resulting in a reduced PRAS40 phosphorylation (Thr246).
AMPK phosphorylation (Thr172) and the induction of autophagy (LC3-II) were evaluated in response to Akti-X. Phospho-specific expres-
sion was verified by comparison with total respective proteins, and β-actin is included as a loading control.
1314 CCL2 is a Negative Regulator of AMPK Roca et al. Neoplasia Vol. 11, No. 12, 2009
adaptive response to nutrient deprivation and cellular stress to recycle
and remove damaged macromolecules and organelles [40]. By mediat-
ing catabolism of intracellular contents, autophagy maintains cellular
bioenergetics during metabolic stress. Starvation, protein aggregation,
and anticancer treatments increase autophagic activity above the basal
levels. In solid tumors, cancer cells at the center of a tumor are poorly
vascularized, and the induction of autophagy may allow these cells to
survive the nutrient depletion stress. However, if the induction of auto-
phagy surpasses the physiological range, it could contribute to cell death,
and therefore, strict regulation is crucial in these nutrient-poor settings
[15,41–43]. Furthermore, most chemotherapy-resistant cancers exhibit
defective apoptosis, and cell death involves the activation of a secondary
mechanism [44].
mTOR serves as a major negative regulator of autophagy [14,45].
mTOR functions as a sensor for cellular energy and amino acid levels
and acts as a metabolic rheostat-controlling protein synthesis during
cellular stress. mTOR links this information with external signals orig-
inating from cell surface receptors, and the sensory input is biochemi-
cally integrated and coupled to a coordinated response that controls
cellular functions. In addition, AMPK is a master regulator of energy
balance in the cell, and once activated, it shuts down energy-consuming
processes and stimulates the catabolic pathways that generate ATP [8].
The AMPK pathway is linked to mTOR signaling through the ability
of AMPK to inhibit mTOR. Thus, the energy demands of protein syn-
thesis can be reduced when cellular energy levels are diminished.We pre-
viously reported that CCL2, a chemokine highly prevalent in the tumor
microenvironment, induces the mTOR pathway and promotes prostate
cancer PC3 cell survival by inhibiting autophagic death through activa-
tion of PI3K/Akt signaling and survivin up-regulation [25,26]. In this
work, we have examined the possible role of CCL2 in regulating the
AMPK activity to control the activation of mTORC1, survivin expres-
sion, and cell survival.
First, it was demonstrated that CCL2 hyperactivates mTORC1 in
prostate cancer PC3 cells and sustains its activation over time as moni-
tored by phosphorylation of p70S6K (Figure 1A). mTORC1 stimulation
was accompanied by a negative regulation of AMPK phosphorylation
on the crucial residue (Thr172) [46] (Figure 1B). Furthermore, raptor,
an essential component of mTORC1 and a direct target of AMPK
[10], was also negatively regulated by CCL2. The AMPK regulation
by CCL2 also correlates with the up-regulation of survivin expression
that was shown to enhance survival through inhibition of autophagic
cell death (Figure 1B) [25].
The significance of AMPK regulation by CCL2 to sustain the
mTORC1 activation and PC3 cell survival was demonstrated by using
Figure 5. CCL2 regulates AMPK signaling in C4-2B and DU145 pros-
tate cancer cells. (A and B) Western blot analysis revealing the in-
hibition of AMPK/raptor phosphorylation by CCL2 in C4-2B (A) and
DU145 (B) prostate cancer cell lines. Reduction in AMPK phosphory-
lation for both C4-2B and DU145, with respect to total protein, was
quantified by densitometric analysis (bar graphs, right). Phospho-
specific expression was verified by comparison with total respective
proteins, and β-actin was evaluated as a loading control.
Figure 4. CCL2-mediated survivin up-regulation and prolonged PC3
cell survival is dependent on p70S6K phosphorylation. (A) Cell viability
was evaluated at increasing time points (24, 48, and 72 hours) in
response to specific p70S6K inhibitor, Bis-V (8 μM). Data are repre-
sentative of n = 5 assays. SD bars are depicted for each data point.
P value was calculated by the Student’s t-test (B) Western blot analy-
sis of cells treated with 8 μM Bis-V in the presence and absence of
CCL2. The inhibitor effect was evaluated by the analysis of p70S6K
phosphorylation (Thr389), LC3 conversion, and survivin expression.
Phospho-specific expression of p70S6K was verified by comparison
with the total protein, and β-actin was included as a loading control.
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the specific AMPK activator D942. Indeed, D942 induced the AMPK
and raptor phosphorylation (Figure 2B), resulting in a significant de-
crease of p70S6K activation by mTORC1 (Figure 2C). Consequently,
the CCL2-induced survivin up-regulation was stunted, correlating with
an increase in autophagosome formation (higher LC3-II reflects higher
autophagy [19,25]) and rapid induction of cell death (Figure 2, A,
a and b, and C ). These findings also corroborate our previous data
showing that CCL2 modulates the amount and localization of LC3
and that survivin short hairpin RNA induces changes in LC3 punctate
pattern that could not be reversed by CCL2 [25]. Furthermore, CCL2-
treated cells exhibited a higher resistance to AMPK activator when
compared with control cells (Figure 2A, a, b, and c), indicating a crucial
role of AMPK signaling in the survival mechanism induced by this cyto-
kine. Concurrently, D942 showed insignificant alteration of Akt activa-
tion (Figure 2B, bar graph), suggesting that the changes inmTORC1 and
cell survival are a direct consequence of AMPK activation.
Conversely, the ATP competitive inhibitor of AMPK, compound C,
induced a strong inhibition of Akt/PRAS40 phosphorylation, and con-
sequently, mTORC1 was also inhibited (Figure 3, B and C ). Although
the inhibitor resulted in lower raptor phosphorylation (Figure 3B), the
mTORC1 complex remained inactive, which could be explained by
the inhibition of Akt signaling. Inhibition of autophagy by using com-
pound C has been reported in other mammalian cells such as HT-29
and HeLa cells [5]. However, in PC3 cells, compound C induced
autophagic death, as evidenced by the increase in autophagosome for-
mation (higher LC3-II) and lower survivin expression (Figure 3, A and
C). In addition, reports in other cells suggest that Akt negatively regu-
lates AMPK phosphorylation [36,37]. However, it was found that
CCL2-mediated AMPK regulation is independent of Akt signaling.
In fact, the Akt-specific inhibitor X (Akti-X) effectively blocked Akt/
PRAS40 phosphorylation and stimulated autophagy (increase in
LC3-II); conversely, AMPK was not activated by Akti-X (Figure 3D).
In summary, these results suggest that AMPK functions in parallel to
Akt signaling; nevertheless, both pathways are indispensable for the
induction of mTORC1 signaling and promotion of cell survival. In-
dependent inactivation of any of these two CCL2-induced signals will
blunt mTORC1 activity and induce cell death. Moreover, the pre-
sented findings also suggest an important physiological role of raptor
phosphorylation by AMPK in the control of autophagy. Importantly,
this study also shows that under serum deprivation, CCL2 induces a
negative regulation of AMPK in other prostate cancer cells: C4-2B
and DU145 (Figure 5, A and B). In these cells, survivin is also up-
regulated by CCL2 [25], suggesting that CCL2 induces an analogous
survival mechanism.
Further significance of p70S6K phosphorylation at Thr389 came from
the findings that the p70S6K-specific inhibitor, Bis-V, also stunted sur-
vivin expression and induced autophagy and cell death (Figure 4, A
and B). Because CCL2 is a negative regulator of AMPK, and p70S6K
phosphorylation is inhibited by AMPK, these results imply that this is
a major mechanism used by CCL2 to control survivin expression and
induce prostate cancer cell survival. Figure 6 summarizes this mecha-
nism: CCL2 induces a negative regulation of AMPK and a positive
regulation of Akt, and both signaling pathways act in parallel and are
necessary to sustain mTORC1 activation and p70S6K phosphorylation
to induce survivin up-regulation and promote cell survival.
Growing evidence suggests that signaling abnormalities within nu-
trient signaling pathways can lead to cancer. For example, the AMPK
kinase, LKB1, is a tumor suppressor protein that activates AMPKwhen
the AMP/ATP ratio increases in starved cells [47,48]. Mutations in the
AMPK kinase, LKB1, are associated with several types of related can-
cers [47,49,50]. Although it is not clear how CCL2 exerts AMPK regu-
lation, the findings presented here suggest that CCL2 does not
induce metabolic changes that affect the ATP concentration in the cell
(Figure 1C ). Nevertheless, the fact that CCL2 regulates AMPK sig-
naling pathway to sustain mTORC1 activation, survivin expression,
and survival in prostate cancer cells suggests that CCL2 and AMPK
may serve as therapeutic targets for the treatment of prostate cancer.
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